B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas

Modern Pathology

Volumn 28, Issue 2, 2015, Pages 208-217

  Li, Shaoying ^a   Seegmiller, Adam C ^a   Lin, Pei ^b   Wang, Xuan J ^a   Miranda, Roberto N ^b   Bhagavathi, Sharathkumar ^c   Medeiros, L Jeffrey ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; MEMBRANE METALLOENDOPEPTIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CYTOGENETICS; DOUBLE HIT LYMPHOMA; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MALE; MORPHOLOGY; NONHODGKIN LYMPHOMA; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; BIOSYNTHESIS; GENETICS; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; GENES, BCL-2; GENES, MYC; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEPRILYSIN; YOUNG ADULT;

EID: 84922064874     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.95     Document Type: Article

References (40)

1. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319-2331.
2. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012;151:68-79.
3. Smith SM, Anastasi J, Cohen KS, et al. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol Dis 2010;45:317-323.
4. Bueno MJ, Gomez de Cedron M, Gomez-Lopez G, et al. Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood 2011;117:6255-6266.
5. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
6. Frenzel A, Loven J, Henriksson MA. Targeting MYCregulated miRNAs to combat cancer. Genes Cancer 2010;1:660-667.
7. Han SS, Yun H, Son DJ, et al. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer 2010;9:97.
8. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010;149:484-497.
9. Leskov I, Pallasch CP, Drake A, et al. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene 2013;32:1066-1072.
10. Li S, Lin P, Young KH, et al. MYC/BCL2 double-hit high-grade B-Cell lymphoma. Adv Anat Pathol 2013; 20:315-326.
11. Marin MC, Hsu B, Stephens LC, et al. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res 1995;217:240-247.
12. Shaffer AL 3rd, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012;30:565-610.
13. Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-kappaB targets BCL2 and BIRC5/ Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005;206: 123-134.
14. Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012;22:506-523.
15. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34:327-340.
16. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009;94:935-943.
17. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273-2279.
18. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006;19:25-33.
19. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007;92:1335-1342.
20. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25:145-156.
21. Lin P, Medeiros LJ. High-grade B-cell lymphoma/ leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica 2007;92:1297-1301.
22. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999;17:1558-1567.
23. Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23:777-783.
24. Pedersen MO, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience. Eur J Haematol 2012;89:63-71.
25. Kluin PM, Harris NL, Stein H, Leoncini L, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (ed) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC: Lyon; 2008, pp 265-267.
26. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012;26:2103-2113.
27. Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 2013;98:255-263.
28. Johnson NA, Slack GW, Savage KJ, et al. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol 2012;30:3452-3459.
29. Shaffer LG, McGowan-Jordan J, M (eds) An International System for Human Cytogenetic Nomenclature. Karger: Basel, Switzerland, 2013.
30. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460-3467.
31. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013;98:1554-1562.
32. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
33. Mossafa H, Damotte D, Jenabian A, et al. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma 2006;47:1885-1893.
34. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013;98:1554-1562.
35. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121:4021-4031.
36. Testoni M, Kwee I, Greiner TC, et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol 2011;155:274-277.
37. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology 2008;53:205-217.
38. Jiang HY, Li HL, Hu H, et al. [Detection of t (14; 18) translocation and bcl-2 amplification in diffuse large B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi 2007;36:84-89.
39. Kusumoto S, Kobayashi Y, Sekiguchi N, et al. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a 'nongerminal center phenotype'. Am J Surg Pathol 2005; 29:1067-1073.
40. Monni O, Joensuu H, Franssila K, et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997;90: 1168-1174.